SS Innovations International (NASDAQ: SSII) Expands Global Footprint as SSi Mantra Procedures Reach 14,103

At a glance

Company: SS Innovations International
Ticker: NASDAQ: SSII
Announcement: Expansion

Key figures

Installed SSi Mantra systems: 238
Countries with installed systems: 12
Cumulative procedures: 14,103
Procedure increase from end of 2025: 79%
Cumulative robotic telesurgeries: 188
Physicians trained: approximately 1,500

Products and programs

SSi Mantra surgical robotic system

The company reported continued growth of its SSi Mantra surgical robotic system, with installations reaching 238 as of September 8, 2026, with the installed base now spanning 12 countries, following recent launches in Colombia and Sri Lanka and further international expansion.
The company said cumulative SSi Mantra procedures reached 14,103, a 79% increase from 7,885 at the end of 2025.
Pediatric applications continue to expand, including a robotic kidney procedure performed on a 45-day-old infant in India using 5-millimeter instruments.
SS Innovations reported 188 cumulative robotic telesurgeries as of August 31, alongside long-distance procedures connecting surgeons and patients across countries.
The company expects FDA review of its 510(k) submission by the end of Q1 2027 and believes EU CE marking for SSi Mantra could be obtained by the end of 2026.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is reporting continued growth in the use of its SSi Mantra surgical robotic system, with the company’s installed base and procedure count increasing as it expands into new countries and surgical applications.

In an update issued September 10, the company said 238 SSi Mantra systems were installed as of September 8, up 42% from 168 at the end of 2025. Procedures performed with the system reached 14,103, representing a 79% increase from 7,885 at year-end. The company also said approximately 1,500 physicians have now been trained on SSi Mantra, which has been used in…

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

Questions around this news

How many SSi Mantra systems have been installed, and how many procedures have been performed?
SS Innovations reported 238 installed systems as of September 8, 2026, across 12 countries. The company said the system had been used in 14,103 procedures, compared with 7,885 at the end of 2025.
What is the regulatory status of the SSi Mantra in the United States and Europe?
The company said it expects the U.S. Food and Drug Administration to review its 510(k) submission by the end of the first quarter of 2027. It also said it believes European Union CE marking for the system could be obtained by the end of 2026.
What pediatric procedures has the SSi Mantra been used for?
The release says pediatric uses are expanding and describes a robotic kidney procedure performed in India on a 45-day-old infant. The procedure used 5-millimeter instruments. The release does not provide further clinical details about the case or describe other pediatric procedures.

SEC filings

Earlier from SS Innovations International

Back to News Center

SS Innovations International (NASDAQ: SSII) Expands Global Footprint as SSi Mantra Procedures Reach 14,103